Shots:
- Labcorb acquires the Vectra RA test from Myriad Genetics along with other operating assets and IP for $150M in cash. The transaction is expected to close in Q3’21
- The divestiture of Myriad auto immune’s Vectra testing business allow Labcorb to bolster its rheumatology and autoimmune portfolios
- Vectra is a non-invasive, blood-based test that analyzes 12 biomarkers to measure RA disease activity. It has been used by ~1M patients to understand their RA disease activity
Click here to read full press release/ article | Ref: Businesswire | Image: Wikipedia
The post Labcorp to Acquire Myriad’s Vectra Testing Business for $150M first appeared on PharmaShots.
